science
Prime Medicine Wins Arbitration Against Beam Therapeutics Over Gene-Editing Agreement
An arbitrator ruled that Prime Medicine's work on an AATD drug did not violate a 2019 agreement with Beam Therapeutics. The decision clears the way for Prime to begin a clinical trial this quarter.
Jul 9, 6:28 PM·1m read2 sources
biopharmadive.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Prime Medicine said Wednesday that it had won an arbitration dispute against Beam Therapeutics. The ruling found that Prime's work on a gene-editing drug for alpha-1 antitrypsin deficiency did not violate a 2019 agreement between the two companies. The companies were both spun out of the same lab and had been barred from competing under the earlier contract.
The arbitrator's decision resolves the dispute for now.
The ruling allows Prime Medicine to start a clinical trial for the liver disease treatment this quarter. Prime's stock rose 11 percent on the news Wednesday morning. The outcome represents a setback for Beam Therapeutics, which had challenged the work under the 2019 agreement.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationModerate · 2 sources
